美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

百濟神州

376.37

+4.391.18%

盤前：379.513.14+0.83%04:06 EDT

成交量：39.63萬

成交額：1.49億

市值：429.06億

市盈率：67.34

高：380.00

開：370.12

低：369.49

收：371.98

52周最高：385.22

52周最低：253.95

股本：1.14億

流通股本：8,569.35萬

量比：1.04

換手率：0.46%

股息：- -

股息率：- -

每股收益(TTM):5.59

每股收益(LYR):2.47

淨資產收益率：14.66%

總資產收益率：7.46%

市淨率：8.29

市盈率(LYR):152.38

資料載入中...

總覽公司新聞資訊公告

中金：百濟神州「跑贏行業」維持評級目標價升至266港元

百濟神州：胰腺癌中KRAS突變率約95%、MTAP缺失率約20%，重疊人群較容易識別

证券日报网

中概股龍頭指數盤初上漲0.75%

每日经济新闻

百濟神州：百悦達目前由外部CMO供應，各環節均按計劃推進

证券日报网

異動解讀｜百濟神州盤中上漲5.49%，Q2業績大超預期疊加多家機構上調目標價

百濟神州：公司在MCL已形成百悦澤、百悦達及後續聯合方案的多層次佈局

百濟神州：公司擬披露CEA ADC在非小細胞肺癌中的早期數據，覆蓋鱗癌和非鱗癌患者

百濟神州：GPC3x4-1BB從進入臨床到啓動潛在註冊性2期研究僅約19個月

百濟神州：百悦澤在CLL/SLL新患中的佔比已超過50%

百濟神州：公司已停止原Pan-KRAS抑制劑BGB-53038的開發，但並未退出RAS賽道

異動解讀｜百濟神州盤前上漲5.48%，Q2業績大超預期疊加多家機構上調目標價

美股中概股盤前升跌互現，百濟神州漲5%

異動解讀｜百濟神州夜盤上漲5.16%，Q2業績超預期疊加多家機構上調目標價

里昂：百濟神州維持「跑贏大市」評級目標價上調至321.70港元

百濟神州（06160）上漲2.6% 業績表現強勁並上調年度業績指引

研報掘金丨中金：百濟神州次季業績勝預期，H股目標價升至266港元

【券商聚焦】招銀國際維持百濟神州（ONC/06160）「買入」評級指血液瘤優勢穩固

港股異動 | 百濟神州(06160)績後漲近4% 上半年經調整淨利按年增長111% 公司實體瘤領域再取得進展

百濟神州二季報：A股創新藥龍頭，上半年淨利潤漲了386%

红星资本局

「創新藥雙雄」半年業績同台：百濟神州賺全球的錢，信達生物吃國內的飯，行業跨過「燒錢拐點」

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/ONC/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":376.37,"timestamp":1787688000000,"preClose":371.98,"halted":0,"volume":396290,"hourTrading":{"tag":"盘前","latestPrice":379.51,"preClose":376.37,"latestTime":"04:06 EDT","volume":86,"amount":32640.141580000003,"timestamp":1787731568851,"change":3.14,"changeRate":0.008343,"amplitude":0.000106},"delay":0,"changeRate":0.011801709769342401,"floatShares":85693500,"shares":113999999,"eps":5.589356,"marketStatus":"盤前交易","change":4.39,"latestTime":"08-26 05:05:32 EDT","open":370.12,"high":380,"low":369.49,"amount":149441771.39450002,"amplitude":0.028254,"askPrice":385.35,"askSize":3,"bidPrice":373,"bidSize":5,"shortable":3,"etf":0,"ttmEps":5.589356,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787751000000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":376.37,"preHourTrading":{"tag":"盘前","latestPrice":379.51,"preClose":376.37,"latestTime":"04:06 EDT","volume":86,"amount":32640.141580000003,"timestamp":1787731568851,"change":3.14,"changeRate":0.008343,"amplitude":0.000106},"postHourTrading":{"tag":"盘后","latestPrice":375,"preClose":376.37,"latestTime":"19:30 EDT","volume":50505,"amount":19007500.59,"timestamp":1787700602016,"change":-1.37,"changeRate":-0.00364,"amplitude":0.00364},"volumeRatio":1.0377669770162585,"impliedVol":0.3279,"impliedVolPercentile":0.008},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":85693500,"roa":"7.46%","roe":"14.66%","lyrEps":2.469999,"volumeRatio":1.0377669770162585,"shares":113999999,"dividePrice":0,"high":380,"amplitude":0.028254,"preClose":371.98,"low":369.49,"week52Low":253.9475,"pbRate":"8.29","psRate":"7.00","week52High":385.22,"institutionHeld":0,"latestPrice":376.37,"committee":0.25,"eps":5.589356,"divideRate":0,"volume":396290,"delay":0,"ttmEps":5.589356,"open":370.12,"prevYearClose":303.81,"prevWeekClose":374.47,"prevMonthClose":316.01,"prevQuarterClose":284.97,"fiveDayClose":369.15,"twentyDayClose":330.46,"sixtyDayClose":287.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"ONC","fiscalQuarterEnding":"2026/06","expectedEps":1.4,"name":null,"time":"盤前","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"pre","actualEps":2.05},{"market":"US","date":"2026-05-06","symbol":"ONC","fiscalQuarterEnding":"2026/03","expectedEps":0.73,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":1.96},{"market":"US","date":"2026-02-26","symbol":"ONC","fiscalQuarterEnding":"2025/12","expectedEps":1.6,"name":null,"time":"盤前","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"pre","actualEps":0.58},{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.6786,"hold":0,"sell":0.0357,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6786,"analysts":28,"updateTime":1783915200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-08-25","current":67.336917,"percent":0.720143,"low":-217.585346,"twenty":-72.828407,"median":-26.085316,"eighty":109.781194,"high":609.337035,"avg":44.137904,"sd":211.520738,"marketCap":42294824206},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-09","current":517.162439,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"marketCap":35451485198},{"date":"2026-01-16","current":546.090088,"twenty":-85.828543,"median":-40.382553,"eighty":-21.503627,"marketCap":37434475537},{"date":"2026-01-23","current":546.929506,"twenty":-85.639801,"median":-40.307741,"eighty":-21.22036,"marketCap":37492017667},{"date":"2026-01-30","current":564.993144,"twenty":-85.550958,"median":-40.153659,"eighty":-20.966373,"marketCap":38730280050},{"date":"2026-02-06","current":560.150346,"twenty":-85.195011,"median":-40.102874,"eighty":-20.825389,"marketCap":38398306221},{"date":"2026-02-13","current":559.214072,"twenty":-84.275105,"median":-39.916618,"eighty":-20.627155,"marketCap":38334124614},{"date":"2026-02-20","current":572.225057,"twenty":-83.309792,"median":-39.846883,"eighty":-20.486836,"marketCap":39226027634},{"date":"2026-02-27","current":124.64483,"twenty":-82.630374,"median":-39.542215,"eighty":-20.122622,"marketCap":35764714896},{"date":"2026-03-06","current":113.265677,"twenty":-81.639564,"median":-39.274234,"eighty":-19.815709,"marketCap":32499660582},{"date":"2026-03-13","current":110.254986,"twenty":-80.905934,"median":-38.936161,"eighty":-19.52935,"marketCap":31635793773},{"date":"2026-03-20","current":109.257937,"twenty":-80.698984,"median":-38.812817,"eighty":-19.378455,"marketCap":31349707731},{"date":"2026-03-27","current":107.028105,"twenty":-78.593786,"median":-38.554628,"eighty":106.63856,"marketCap":30709895147},{"date":"2026-04-02","current":119.197503,"twenty":-77.951,"median":-38.396659,"eighty":109.305857,"marketCap":34201697271},{"date":"2026-04-10","current":121.122038,"twenty":-77.761122,"median":-38.192039,"eighty":109.972102,"marketCap":34753909865},{"date":"2026-04-17","current":123.949552,"twenty":-77.38927,"median":-37.882149,"eighty":113.865362,"marketCap":35565216938},{"date":"2026-04-24","current":115.875632,"twenty":-77.050014,"median":-37.033118,"eighty":115.720164,"marketCap":33248542844},{"date":"2026-05-01","current":114.357667,"twenty":-76.68,"median":-35.397875,"eighty":115.720164,"marketCap":32812988374},{"date":"2026-05-08","current":68.695502,"twenty":-76.462018,"median":-34.468285,"eighty":115.560959,"marketCap":35242166242},{"date":"2026-05-15","current":66.012693,"twenty":-76.246744,"median":-33.418249,"eighty":115.518333,"marketCap":33865831800},{"date":"2026-05-22","current":67.096218,"twenty":-76.102676,"median":-31.546239,"eighty":115.492019,"marketCap":34421701930},{"date":"2026-05-29","current":62.970154,"twenty":-75.880486,"median":-30.693232,"eighty":115.373164,"marketCap":32304948475},{"date":"2026-06-05","current":60.662245,"twenty":-75.223997,"median":-29.59006,"eighty":115.163248,"marketCap":31120945098},{"date":"2026-06-12","current":56.401824,"twenty":-74.640704,"median":-29.253094,"eighty":114.989528,"marketCap":28935263747},{"date":"2026-06-18","current":56.924083,"twenty":-74.490547,"median":-29.223519,"eighty":114.833736,"marketCap":29203193149},{"date":"2026-06-26","current":59.667569,"twenty":-74.312777,"median":-29.026044,"eighty":114.683445,"marketCap":30610656318},{"date":"2026-07-02","current":63.004827,"twenty":-74.195313,"median":-28.914242,"eighty":114.357667,"marketCap":32322736319},{"date":"2026-07-10","current":65.624791,"twenty":-74.135535,"median":-28.781271,"eighty":113.811576,"marketCap":33666830293},{"date":"2026-07-17","current":68.786518,"twenty":-74.11053,"median":-28.668245,"eighty":113.265677,"marketCap":35288859332},{"date":"2026-07-24","current":70.81271,"twenty":-74.11053,"median":-28.275697,"eighty":112.626442,"marketCap":36328336476},{"date":"2026-07-31","current":69.796363,"twenty":-73.864189,"median":-27.361812,"eighty":112.074132,"marketCap":35806930294},{"date":"2026-08-07","current":57.188468,"twenty":-73.321375,"median":-26.690447,"eighty":111.218799,"marketCap":37498879034},{"date":"2026-08-14","current":61.733374,"twenty":-72.9906,"median":-26.519964,"eighty":110.411886,"marketCap":40479005230},{"date":"2026-08-21","current":64.013629,"twenty":-72.865597,"median":-26.24637,"eighty":109.877808,"marketCap":41974184913},{"date":"2026-08-25","current":64.502627,"twenty":-72.828407,"median":-26.085316,"eighty":109.781194,"marketCap":42294824206}],"updateTime":1787735132052},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658679842","title":"中金：百濟神州「跑贏行業」維持評級 目標價升至266港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658679842","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658679842?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 09:40","pubTimestamp":1786239600,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端中金发布研究报告称，综合考虑泽布替尼高增长以及费用控制，上调百济神州（06160）今年盈利预测34%至8.71亿美元，并调升2027年盈测38%至12亿美元。该行维持其“跑赢行业”评级，H股目标价升6.4%至266港元。该行表示，公司第二季业绩胜预期 ，收入同比增长30%，其中产品收入同比增长29%；GAAP预期同比增长151%至2.37亿美元，销售收入略胜于预期，超预期是由于泽布替尼高增长及费用控制良好。报告中提到，百济神州公司大幅上调主要航线，总收入航线预估约66亿至68亿美元；GAAP经营利润指引增至约10亿至11亿美元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-09/doc-inimsnkv3665933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","EWH","688235","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644339","title":"百濟神州：胰腺癌中KRAS突變率約95%、MTAP缺失率約20%，重疊人群較容易識別","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644339","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644339?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:41","pubTimestamp":1786110060,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，MTAP缺失和KRAS突变均属于人类肿瘤中的高频分子事件，理论上存在较多联合机会。胰腺癌中KRAS突变率约95%、MTAP缺失率约20%，重叠人群较容易识别。肺腺癌中KRAS突变在欧美人群约30%、中国人群约10%，再叠加MTAP缺失后目标人群会明显缩小。公司会在肺癌开展探索，其他瘤种则主要根据两类突变的重叠率和早期临床信号确定优先级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfya9837948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfya9837948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LU1251922891.USD","BK4139","LU1770034418.SGD","BK0239","LU1303224171.USD","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","KURE","ONC","BK1588","BK4526","BK4585","BK1500","LU0307460666.USD","06160","LU1719994722.HKD","BK1583","BK1161","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657564189","title":"中概股龍頭指數盤初上漲0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657564189","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657564189?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:32","pubTimestamp":1786109554,"startTime":"0","endTime":"0","summary":"8月7日，利弗莫尔中概股龙头指数盘初上涨0.75%。成分股中，希尔威金属矿业涨8.34%，百济神州涨5.85%，禾赛涨5.38%，奇景光电涨4.87%，传奇生物涨4.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835476887.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835476887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2476274720.SGD","02525","HSAI","BK4526","ONC","688235","MEDI","SLVR","BK4141","HIMX","BK4210","BK4588","LU2476274308.USD","LEGN","06160","MEMS","CANC","BK4139","BK4505","BK4124","SLVX","BK4585","LU2778985437.USD","SVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644388","title":"百濟神州：百悦達 目前由外部CMO供應，各環節均按計劃推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644388","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644388?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:32","pubTimestamp":1786109520,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯，百济神州在接受调研时表示，百悦达目前由外部CMO供应，各环节均按计划推进。公司预计于2026年第三季度末至第四季度初在美国正式商业化上市。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfxz3065588.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfxz3065588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","688235","BK1161","BK1500","BK0239","BK1583","06160","LU0307460666.USD","BK1588","BK4588","LU0588546209.SGD","BK4526","KURE","LU2328871848.SGD","LU1770034418.SGD","LU1969619763.USD","LU1303224171.USD","LU1251922891.USD","LU1719994722.HKD","BK4139","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108163796","title":"異動解讀｜百濟神州盤中上漲5.49%，Q2業績大超預期疊加多家機構上調目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1108163796","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108163796?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:31","pubTimestamp":1786109500,"startTime":"0","endTime":"0","summary":"8月7日，百济神州盘中上涨5.49%，报349.09美元/股，成交额2512.75万美元。消息面上，公司Q2业绩大幅超预期，全球总收入17.05亿美元，同比增长30%；GAAP净利润2.37亿美元，同比增长151%。上半年经调整净利润8.195亿美元，同比增长111%。公司同步上调全年营收指引至449亿元至462亿元，核心产品百悦泽全球收入达12亿美元，同比增长31%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"百济神州盘中上涨5.49%，Q2业绩大超预期叠加多家机构上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641869","title":"百濟神州：公司在MCL已形成百悦澤、百悦達及後續聯合方案的多層次佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641869","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641869?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:29","pubTimestamp":1786109340,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯，百济神州在接受调研时表示，全球MCL每年新发患者约2万人，美国亦有数千例。MANGROVE研究中百悦泽?联合利妥昔单抗相较化疗免疫方案实现HR=0.57，有望改变一线标准治疗；相比之下，阿可替尼ECHO研究是在化疗基础上加用BTK抑制剂，HR约0.73。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835474761.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835474761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","LU1719994722.HKD","LU2328871848.SGD","BK4588","BK1500","LU0588546209.SGD","ONC","LU1969619763.USD","LU1251922891.USD","BK1588","BK1161","LU1303224171.USD","BK4585","KURE","BK0239","BK1583","BK4526","06160","BK4139","688235","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641539","title":"百濟神州：公司擬披露CEA ADC在非小細胞肺癌中的早期數據，覆蓋鱗癌和非鱗癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641539","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:24","pubTimestamp":1786109040,"startTime":"0","endTime":"0","summary":"百济神州在接受调研时表示，公司拟披露CEA ADC在非小细胞肺癌中的早期数据，覆盖鳞癌和非鳞癌患者。具体的CEA表达阈值、PD-L1表达分层及对应疗效尚未对外披露，后续数据将提供更多信息。公司不会将该产品局限于后线，正在加快向更前线及与PD-1等方案联合推进。对于CEA与KRAS共突变等细分人群，也会根据表达重叠度和早期信号开展探索。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","BK4526","06160","LU1770034418.SGD","BK4231","LU1303224171.USD","688235","BK1161","LU1969619763.USD","NETL","ADC","LU2328871848.SGD","LU1719994722.HKD","BK4139","LU0307460666.USD","LU0588546209.SGD","LU1251922891.USD","ONC","KURE","BK1588","BK4588","BK4585","BK4080","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641518","title":"百濟神州：GPC3x4-1BB從進入臨床到啓動潛在註冊性2期研究僅約19個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641518","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641518?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:04","pubTimestamp":1786107840,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，GPC3x4-1BB从进入临床到启动潜在注册性2期研究仅约19个月，完成多个剂量爬坡后仍保持较好的安全性和有效性，体现了公司全球临床执行效率。公司认为研发存在“大闭环”和“小闭环”：百悦泽®从立项到全球商业成功属于大闭环，而新分子在早期临床验证安全性和有效性、并迅速进入注册性开发属于小闭环。2026年多款实体瘤产品同步完成小闭环，说明公司的靶点选择、分子质量和全球开发体系具有较强可复制性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsm4756409.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsm4756409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1588","LU1719994722.HKD","LU1770034418.SGD","KURE","06160","BK4588","BK4526","BK4139","ONC","LU1969619763.USD","LU1251922891.USD","LU0588546209.SGD","BK1500","BK1161","BK4585","LU1303224171.USD","BK0239","BK1583","LU2328871848.SGD","LU0307460666.USD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641513","title":"百濟神州：百悦澤在CLL/SLL新患中的佔比已超過50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641513","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641513?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:04","pubTimestamp":1786107840,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，不同数据源对美国新患份额的统计口径略有差异，但百悦泽®在CLL/SLL新患中的占比已超过50%，处于较高水平。新患份额向收入转化是渐进过程：新增患者会逐年沉淀为存量患者，并随持续治疗时间延长不断贡献收入。当前平均DoT约42个月，预计将随患者累积和数据成熟继续延长，因此百悦泽®还远未达销售峰值。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsi3152709.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsi3152709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","BK1588","LU1969619763.USD","LU1251922891.USD","LU0307460666.USD","KURE","BK4585","BK1500","BK4139","LU1770034418.SGD","06160","688235","LU1303224171.USD","BK1583","BK4588","BK1161","LU2328871848.SGD","BK4526","BK0239","LU1719994722.HKD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641510","title":"百濟神州：公司已停止原Pan-KRAS抑制劑BGB-53038的開發，但並未退出RAS賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641510","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641510?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:04","pubTimestamp":1786107840,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，公司已停止原Pan-KRAS抑制剂BGB-53038的开发，但并未退出RAS赛道。新项目为Pan-RAS分子胶降解剂，与Revolution Medicines的产品类似，但具有包括更高效的KRAS降解、更长且更平稳的PK（可能转化为更好的安全性）以及较好的血脑屏障穿透能力等潜在差异化优势，而后者对脑转移发生率较高的非小细胞肺癌具有潜在意义。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628077.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1251922891.USD","BK1588","KURE","LU1303224171.USD","BGB","BK4588","ONC","LU0588546209.SGD","BK4139","BK4585","LU0307460666.USD","LU2328871848.SGD","BK1161","06160","BK4526","LU1719994722.HKD","BK0239","BK1583","LU1770034418.SGD","LU1969619763.USD","688235","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197216134","title":"異動解讀｜百濟神州盤前上漲5.48%，Q2業績大超預期疊加多家機構上調目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1197216134","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197216134?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 16:03","pubTimestamp":1786089781,"startTime":"0","endTime":"0","summary":"8月7日，百济神州盘前上涨5.48%，报345.87美元/股，成交额71.93万美元。消息面上，公司Q2业绩大幅超预期，全球总收入17.05亿美元，同比增长30%；GAAP净利润2.37亿美元，同比增长151%。上半年经调整净利润8.195亿美元，同比增长111%。业绩发布后，里昂将美股目标价上调至522.5美元，花旗上调至466美元，大华继显上调港股目标价至265港元，招银国际维持\"买入\"评级，指出盈利能力改善叠加丰富研发催化将持续支撑估值上行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州盘前上涨5.48%，Q2业绩大超预期叠加多家机构上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657613185","title":"美股中概股盤前升跌互現，百濟神州漲5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657613185","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657613185?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 16:01","pubTimestamp":1786089683,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BABX","BK4588","BK4585","BBYY","BABO","BK4526","KBUF","BABW","BABU","KBAB","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166625359","title":"異動解讀｜百濟神州夜盤上漲5.16%，Q2業績超預期疊加多家機構上調目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1166625359","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166625359?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:18","pubTimestamp":1786083519,"startTime":"0","endTime":"0","summary":"8月7日，百济神州夜盘上涨5.16%，报346.83美元/股，成交额478.14万美元。消息面上，公司Q2业绩大幅超预期，全球总收入17.05亿美元，同比增长30%；GAAP净利润2.37亿美元，同比增长151%。上半年经调整净利润8.195亿美元，同比增长111%。公司同步上调全年营收指引至449亿元至462亿元，核心产品百悦泽全球收入达12亿美元，同比增长31%。百济神州是一家全球肿瘤学公司，核心产品包括BTK抑制剂Brukinsa及PD-1单抗Tevimbra，管线覆盖血液瘤及实体瘤领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657884694","title":"里昂：百濟神州維持「跑贏大市」評級 目標價上調至321.70港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657884694","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657884694?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:04","pubTimestamp":1786082640,"startTime":"0","endTime":"0","summary":"模拟交易客户端里昂发布研报称，将百济神州目标价由291.9港元上调至321.7港元，对百济神州美股目标价由501.3美元上调至522.5美元，维持“跑赢大市”评级。百济神州第二季度收入同比增长29.6%至17亿美元，纯利同比升151.3%至2.37亿美元，双双超越市场预期，主要受核心产品“百悦泽”销售稳健及经营杠杆效应带动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-07/doc-inimnkup0053911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","EWH","ONC","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161691","title":"百濟神州（06160）上漲2.6% 業績表現強勁並上調年度業績指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161691","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657161691?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 13:48","pubTimestamp":1786081707,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 早盘快速冲高，午后高开高走，现价204.600港元，涨幅2.56%，成交金额2335.7万港元。公司同时上调2026年度经营业绩预测，将全年营收由436亿元至452亿元上调为449亿元至462亿元。招银国际表示，百济神州2Q26业绩表现强劲，收入快速增长、盈利能力持续改善，管理层上调FY26指引。该机构预计百济神州FY26将延续强劲增长，盈利能力改善叠加丰富的研发催化，将持续支撑估值上行。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987734","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0239","LU1770034418.SGD","688235","BK1161","LU1719994722.HKD","LU0307460666.USD","BK4585","BK4526","LU1303224171.USD","BK4139","LU0588546209.SGD","LU2328871848.SGD","BK1588","ONC","KURE","BK4588","LU1969619763.USD","06160","LU1251922891.USD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699636","title":"研報掘金丨中金：百濟神州次季業績勝預期，H股目標價升至266港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699636","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699636?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 13:20","pubTimestamp":1786080011,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1969619763.USD","LU1251922891.USD","BK1588","LU0588546209.SGD","ONC","BK4588","BK1583","BK4139","BK0239","EWH","LU1303224171.USD","LU1719994722.HKD","LU2328871848.SGD","BK4585","688235","LU1770034418.SGD","BK1161","LU0307460666.USD","06160","BK1500","BK4526","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657269999","title":"【券商聚焦】招銀國際維持百濟神州（ONC/06160）「買入」評級 指血液瘤優勢穩固","url":"https://stock-news.laohu8.com/highlight/detail?id=2657269999","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657269999?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 13:17","pubTimestamp":1786079835,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，百济神州 2Q26业绩表现强劲，收入快速增长、盈利能力持续改善，管理层上调FY26指引。1H26收入32.2亿美元、经调整营业利润9.17亿美元，分别达到该机构此前全年预测的50%和63%，超出该机构预期。Beqalzi已获FDA批准用于既往接受BTKi治疗的MCL。ASCO上，CDK4i、GPC3x4-1BB双抗、B7-H4ADC均公布了积极的PoC数据。维持“买入”：该机构预计百济神州FY26将延续强劲增长，盈利能力改善叠加丰富的研发催化，将持续支撑估值上行。维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987728","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160","688235","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657066045","title":"港股異動 | 百濟神州(06160)績後漲近4% 上半年經調整淨利按年增長111% 公司實體瘤領域再取得進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2657066045","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657066045?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 09:57","pubTimestamp":1786067870,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州绩后涨近4%，截至发稿，涨3.66%，报206.8港元，成交额3.62亿港元。消息面上，8月6日，百济神州公布2026年第二季度业绩，全球总收入约17.05亿美元，同比增长30%；GAAP净利润约2.37亿美元，同比增长151%；经调整净利润约4.44亿美元，同比增长76%。里昂表示，该行继续看好百济神州全球商业化进展良好，以及实体瘤新型管线进入后期阶段，因应业绩表现及指引上调，将2026至2028年销售额预测分别上调4%、3.3%及3.2%，纯利预测上调23.5%、12.5%及7.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU1303224171.USD","LU1719994722.HKD","BK1161","BK4585","LU1251922891.USD","688235","LU0588546209.SGD","LU0307460666.USD","VXUS","BK0239","KCAI","BK1583","ONC","06160","LU2328871848.SGD","BK1500","BK1588","BK4588","BK4139","BK4526","KURE","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657963961","title":"百濟神州二季報：A股創新藥龍頭，上半年淨利潤漲了386%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657963961","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657963961?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 19:59","pubTimestamp":1786017587,"startTime":"0","endTime":"0","summary":"百济神州二季报：A股创新药龙头，上半年净利润涨了386%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063834061374.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063834061374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","MEDX","399300","06160","IBBQ","688235","06978","159992","ONC","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680111","title":"「創新藥雙雄」半年業績同台：百濟神州賺全球的錢，信達生物吃國內的飯，行業跨過「燒錢拐點」","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680111","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680111?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 18:54","pubTimestamp":1786013642,"startTime":"0","endTime":"0","summary":"相比老大哥百济神州，创新药二哥信达生物的增速同样亮眼，高盛发布研报称，第二季度产品胜过该行预测的41亿元人民币，反映商业化动能持续加快。创新药企业绩兑现元年：三大难题待解从创新药双雄以及荣昌生物等头部创新药企的业绩公告来看，创新药行业已经跨过盈亏平衡点，从“管线溢价”切到“业绩兑现”。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786011933147703386","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159992","BK1161","LU1770034418.SGD","LU1251922891.USD","LU1969619763.USD","BK4585","LU1303224171.USD","LU1719994722.HKD","01801","BK1589","LU2242644610.SGD","LU2488822045.USD","06978","LU0307460666.USD","BK1583","06160","LU2097828805.USD","LU0455707207.USD","MEDX","ONC","HK0000165453.HKD","688235","LU2097828631.EUR","LU0502904849.HKD","BK0239","BK1500","BK1588","LNGR","LU2328871848.SGD","LU0588546209.SGD","LU2097828474.EUR","BK4588","IBBQ","BK4139","LU2097828557.USD","BK4526","KURE","LU2097828714.EUR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":177,"code":"91000000","status":"200"}]}}